[{"orgOrder":0,"company":"Allergopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"rBet v1-FV","moa":"Allergen cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Allergopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergopharma \/ Undisclosed"},{"orgOrder":0,"company":"Allergopharma","sponsor":"Inflamax Research","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Allergovit","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Allergopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergopharma \/ Inflamax Research","highestDevelopmentStatusID":"8","companyTruncated":"Allergopharma \/ Inflamax Research"},{"orgOrder":0,"company":"Allergopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Grass Pollen Allergen","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Allergopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergopharma \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Allergopharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Allergovit is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinoconjunctivitis, Allergic.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          November 21, 2014

                          Lead Product(s) : Allergovit

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase II

                          Sponsor : Inflamax Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : RBet v1-FV is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinoconjunctivitis, Allergic.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 13, 2011

                          Lead Product(s) : rBet v1-FV

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : RPhleum (Grass Pollen Allergen) is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinoconjunctivitis, Allergic.

                          Product Name : rPhleum

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          May 16, 2011

                          Lead Product(s) : Grass Pollen Allergen

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank